Naquotinib

N/A

Report date: 2022/10/25 13:05:08
NME

Base Information

Drug NameNaquotinib
Drug Alias Name那廓替尼NaquotinibumNaquotinib mesylate (Prop INN)ASP-8273
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma Tech Co Ltd Yaizu Technology CenterAstellas Pharma IncAstellas Pharma Global Development Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A